Algemeen Ziekenhuis AZ Klina - Borstkliniek

Brasschaat 2930

0 studies enrolling now · 2 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Relapsed Small Cell Lung Cancer, Residual Invasive Breast Cancer

Studies at this site

• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) — Completed
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling